HIF-1{alpha} and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC

Conclusion: This is the first study to investigate the alteration of expression levels of HIF-1α and mTOR under selective tyrosine kinase inhibition in both p16-positive and -negative SCC. Our findings provide novel insights for a better understanding of HIF-1α and mTOR in the tumor biology of HNSCC and their interaction with selective small-molecule inhibitors.

Source: Cancer Genomics and Proteomics - April 25, 2018 Category: Cancer & Oncology Authors: KRAMER, B., POLIT, M., BIRK, R., ROTTER, N., ADERHOLD, C. Tags: Article Source Type: research